Detall de la convocatòria
Característiques
Característica |
---|
Objectiu de la convocatòria
IMI is a partnership between the European Union and the European pharmaceutical industry, represented by the European Federation of Pharmaceutical Industries and Associations (EFPIA). The goal of the Innovative Medicines Initiative 2 (IMI 2) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. It will build on the successes and lessons learnt under IMI. Like IMI, it will bring together companies, universities, public laboratories, innovative small and medium-sized enterprises (SMEs), patient groups and regulators in collaborative projects that will pave the way for breakthrough vaccines, medicines and treatments to tackle Europe’s growing health challenges, and secure the future international competitiveness of Europe’s pharmaceutical industry. |
Característiques principals
The Call has the following topics: |
Característiques principals
This Call is being run in a two stage submission and evaluation process. Short proposals for this call can only be done through the IMI SOFIA software tool: https://sofia.imi.europa.eu/Pages/Login.aspx?ReturnUrl=%2fPages%2fDefault.aspx |
Lloc de presentació
El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a: Servei de Recerca. C/ Doctor Aiguader, 88. 08003 Barcelona. Tel.: 93.316.04.00. • Carol Barnwell, cbarnwell@imim.es. Ext.: 1670 • Marta López, mlopez4@imim.es Ext.: 1576 |
Convocatòria (URL)
http://www.imi.europa.eu/content/stage-1-16 |
Dotació
IMI JU collaborative projects are implemented through a co-financing scheme. The IMI JU grants financial support to the eligible entities, while the other entities (including the EFPIA companies) participate in the project with their own resources. The EU contribution is: |
Arxius
Arxiu |
---|
Call text |
Guide for submission, evaluation and grant award |